For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Fluocinolone acetonide - Diabetic macular oedema
PAD Profile : Fluocinolone acetonide - Diabetic macular oedema Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves fluocinolone acetonide intravitreal implant as a treatment option in line with the recommendations made in NICE TA953, for treating diabetic macular oedema.
Fluocinolone acetonide for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a Diabetic Macular Oedema (DMO) treatment pathway attached below for information.